Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), a commercial-stage biotechnology company with a market capitalization of ...

Arcturus Therapeutics Holdings Inc. stock is down 46% since Sept. 2023 coverage; mRNA sector faces headwinds with public ...

The company's key products include KOSTAIVE for COVID-19 and LUNAR-FLU for influenza. Arcturus has forged significant partnerships, most notably with CSL (OTC:CSLLY) Seqirus for vaccine ...

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan, President and Representative Director: Daikichiro Kobayashi) ...

Fintel reports that on January 28, 2025, BTIG initiated coverage of Arcturus Therapeutics Holdings (NasdaqGM:ARCT) with a Buy ...

Additionally, Arce’s valuation considers the broader pipeline of Arcturus, including its COVID-19 vaccine and its mRNA-based therapies for cystic fibrosis and ornithine transcarbamylase ...

potential regulatory developments in Japan for their COVID-19 treatment Kostaive, along with existing orders, signify a strong revenue stream. Collectively, these elements underscore Arcturus ...

NAMAKOR Holdings is pleased to announce the acquisition of Metallomax Inc., a Quebec-based leader in the manufacturing of specialized lift platforms. Showcasing a Quebec-Based Success Founded in 2005 ...

On ARCT's third-quarter 2024 earnings call, investors' focus is likely to be on the upcoming launch of its COVID-19 vaccine, Kostaive and other pipeline updates. SAN DIEGO, October 31, 2024--Arcturus ...

Gilead Sciences meanwhile is partnering with Gritstone on an HIV vaccine and Arcturus Therapeutics is working on candidates for flu and COVID-19. Join the conversation, on Tuesday 28th January ...